✦ LIBER ✦

Accelerated fractionation radiotherapy and late intensification with 2 intra-arterial cisplatin infusions for locally advanced head and neck squamous cell carcinoma

✍ Scribed by Kwok Hung Yu; Simon C. H. Yu; Edwin P. Hui; Michael K. M. Kam; Alexander C. Vlantis; Edmund Yuen; Anthony T. C. Chan

Publisher: John Wiley and Sons
Year: 2009
Tongue: English
Weight: 117 KB
Volume: 32
Category: Article
ISSN: 1043-3074
DOI: 10.1002/hed.21279

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Background

This study was established to determine the maximum tolerated dose of intra‐arterial cisplatin (IAC) concurrent with accelerated fractionation radiotherapy for locally advanced head and neck squamous cell carcinoma (HNSCC).

Methods

We conducted a phase I study. Treatment consisted of 70 Gy/35 fractions/5.8 weeks and 2 weekly IAC infusions during the last 2 weeks.

Results

Ten patients were recruited. Two patients had stage III, 1 had stage IVa, and 7 had stage IVb disease. Three patients received IAC at 100 mg/m^2^, 3 at 125 mg/m^2^, and 4 at 150 mg/m^2^. Nine patients received both planned infusions. Dose‐limiting toxicity occurred at 150 mg/m^2^ as transient grade 4 leukopenia and prolonged grade 3 acute skin reactions. The maximum tolerated dose was 125 mg/m^2^. Six patients survived disease‐free at 39 to 67 months.

Conclusions

It was feasible to give IAC concurrent with accelerated fractionation radiotherapy for locally advanced HNSCC. The maximum tolerated dose of cisplatin was 125 mg/m^2^. © 2009 Wiley Periodicals, Inc. Head Neck, 2009

📜 SIMILAR VOLUMES

Prognostic significance of p16 in locall

Prognostic significance of p16 in locally advanced squamous cell carcinoma of the head and neck treated with concurrent cisplatin and radiotherapy

✍ Harold Y. Lau; Sony Brar; Alexander C. Klimowicz; Stephanie K. Petrillo; Desirée 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 328 KB 👁 2 views

## Abstract ## Background Human papillomavirus (HPV)–related squamous cell cancer of the head and neck (SCCHN) has emerged as a distinct clinical entity. The expression of p16 protein can be used as a surrogate for HPV status. ## Methods p16 immunohistochemistry (IHC) was assessed in archival pa

Concomitant low-dose cisplatin and three

Concomitant low-dose cisplatin and three-dimensional conformal radiotherapy for locally advanced squamous cell carcinoma of the head and neck: Analysis of survival and toxicity

✍ Harold Lau; Sony Brar; Desiree Hao; Jack MacKinnon; Don Yee; Stefan Gluck 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 159 KB 👁 2 views

Background. Our center sought to implement a simple chemoradiotherapy schedule for patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) with minimal toxicity to achieve rates of overall survival comparable to other schedules. Methods. The chemoradiotherapy schedule co

High-dose intra-arterial cisplatin and c

High-dose intra-arterial cisplatin and concurrent hyperfractionated radiation therapy in patients with locally advanced primary squamous cell carcinoma of the head and neck: Report of a phase II study

✍ William F. Regine; Joseph Valentino; William John; Gayle Storey; David Sloan; Da 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 106 KB 👁 3 views

Quality-adjusted survival analysis of Ra

Quality-adjusted survival analysis of Radiation Therapy Oncology Group (RTOG) 90-03: Phase III randomized study comparing altered fractionation to standard fractionation radiotherapy for locally advanced head and neck squamous cell carcinoma

✍ Andre A. Konski; Kathryn Winter; Bernard F. Cole; Kie-Kian Ang; Karen K. Fu 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 186 KB 👁 2 views

## Abstract ## Background. To evaluate quality‐adjusted survival (QAS) of patients with locally advanced squamous cell carcinoma of the head and neck treated with 4 different radiation fractionation schedules. ## Methods. QAS was calculated using the quality‐adjusted time without toxicity or rel

Evaluation of 96-hour infusion fluoroura

Evaluation of 96-hour infusion fluorouracil plus cisplatin in combination with alpha interferon for patients with advanced squamous cell carcinoma of the head and neck. A southwest oncology group study

✍ Maha Hussain; Jacqueline Benedetti; Roy E. Smith; Gladys I. Rodriguez; David Sch 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 456 KB 👁 2 views

Phase I and initial phase II results fro

Phase I and initial phase II results from a trial investigating weekly docetaxel and carboplatin given neoadjuvantly and then concurrently with concomitant boost radiotherapy for locally advanced squamous cell carcinoma of the head and neck

✍ David L. Schwartz; R. Bruce Montgomery; Bevan Yueh; Michael Donahue; Yoshimi Anz 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 113 KB 👁 2 views

## Abstract ## BACKGROUND The current Phase I/II study assessed induction docetaxel/carboplatin given weekly for 4 weeks, followed by weekly docetaxel/carboplatin and concomitant boost radiotherapy (CB‐XRT) for locally advanced head and neck squamous cell carcinoma. ## METHODS Twenty patients wi